Compare ALAR & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALAR | LUNG |
|---|---|---|
| Founded | 2013 | 1995 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Industrial Specialties |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 62.1M | 57.9M |
| IPO Year | 2018 | 2020 |
| Metric | ALAR | LUNG |
|---|---|---|
| Price | $8.10 | $1.44 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 7 |
| Target Price | ★ $14.00 | $5.38 |
| AVG Volume (30 Days) | 89.8K | ★ 567.9K |
| Earning Date | 05-28-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 7.64 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $90,497,000.00 |
| Revenue This Year | $24.51 | $2.48 |
| Revenue Next Year | $33.43 | $18.46 |
| P/E Ratio | $44.31 | ★ N/A |
| Revenue Growth | N/A | ★ 8.01 |
| 52 Week Low | $5.50 | $1.13 |
| 52 Week High | $18.00 | $3.88 |
| Indicator | ALAR | LUNG |
|---|---|---|
| Relative Strength Index (RSI) | 43.15 | 54.31 |
| Support Level | $6.65 | $1.39 |
| Resistance Level | $10.43 | $1.45 |
| Average True Range (ATR) | 0.63 | 0.11 |
| MACD | -0.22 | 0.00 |
| Stochastic Oscillator | 13.86 | 74.60 |
Alarum Technologies Ltd is a software-as-a-service (SaaS) provider operating mainly in the web data collection market, offering web data collection and a private internet browsing platform. The company's Web Data Collection products offer secure, fast, and anonymous IP Proxy Network Solutions & Services, or IPPN or IPPN Solutions, to its business customers which, in turn, enables them to anonymously and securely browse the internet as well as to collect data from any publicly available source on the web, for their business purpose. The company operates in one segment: web data collection. Geographically, it derives maximum revenue from China, followed by the United States, Europe, Hong Kong, Asia-Pacific, U.K. Virgin Islands, Israel, United Arab Emirates, Middle East & Africa and other.
Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.